These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 27324768)
21. Impact of augmented renal clearance on the pharmacokinetics of linezolid: Advantages of continuous infusion from a pharmacokinetic/pharmacodynamic perspective. Barrasa H; Soraluce A; Usón E; Sainz J; Martín A; Sánchez-Izquierdo JÁ; Maynar J; Rodríguez-Gascón A; Isla A Int J Infect Dis; 2020 Apr; 93():329-338. PubMed ID: 32112965 [TBL] [Abstract][Full Text] [Related]
22. Clinical pharmacokinetic/pharmacodynamic profile of linezolid in severely ill intensive care unit patients. Dong H; Wang X; Dong Y; Lei J; Li H; You H; Wang M; Xing J; Sun J; Zhu H Int J Antimicrob Agents; 2011 Oct; 38(4):296-300. PubMed ID: 21741222 [TBL] [Abstract][Full Text] [Related]
23. Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance? Udy AA; Lipman J; Jarrett P; Klein K; Wallis SC; Patel K; Kirkpatrick CM; Kruger PS; Paterson DL; Roberts MS; Roberts JA Crit Care; 2015 Jan; 19(1):28. PubMed ID: 25632974 [TBL] [Abstract][Full Text] [Related]
24. Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients. Matsumoto K; Shigemi A; Takeshita A; Watanabe E; Yokoyama Y; Ikawa K; Morikawa N; Takeda Y Int J Antimicrob Agents; 2014 Sep; 44(3):242-7. PubMed ID: 25108880 [TBL] [Abstract][Full Text] [Related]
26. Linezolid in liver failure: exploring the value of the maximal liver function capacity (LiMAx) test in a pharmacokinetic pilot study. Wicha SG; Frey OR; Roehr AC; Pratschke J; Stockmann M; Alraish R; Wuensch T; Kaffarnik M Int J Antimicrob Agents; 2017 Oct; 50(4):557-563. PubMed ID: 28711678 [TBL] [Abstract][Full Text] [Related]
27. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion. Adembri C; Fallani S; Cassetta MI; Arrigucci S; Ottaviano A; Pecile P; Mazzei T; De Gaudio R; Novelli A Int J Antimicrob Agents; 2008 Feb; 31(2):122-9. PubMed ID: 18055183 [TBL] [Abstract][Full Text] [Related]
28. Evaluation of pharmacokinetic target attainment and hematological toxicity of linezolid in pediatric patients. Abouelkheir M; Aldawsari MR; Ghonem L; Almomen A; Alsarhani E; Alsubaie S; Alqahtani S; Kurdee Z; Alsultan A Eur J Clin Pharmacol; 2024 Nov; 80(11):1807-1817. PubMed ID: 39183194 [TBL] [Abstract][Full Text] [Related]
29. Subtherapeutic initial β-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. Udy AA; Varghese JM; Altukroni M; Briscoe S; McWhinney BC; Ungerer JP; Lipman J; Roberts JA Chest; 2012 Jul; 142(1):30-39. PubMed ID: 22194591 [TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic studies of linezolid and teicoplanin in the critically ill. Whitehouse T; Cepeda JA; Shulman R; Aarons L; Nalda-Molina R; Tobin C; MacGowan A; Shaw S; Kibbler C; Singer M; Wilson AP J Antimicrob Chemother; 2005 Mar; 55(3):333-40. PubMed ID: 15705641 [TBL] [Abstract][Full Text] [Related]
31. Linezolid plasma and intrapulmonary concentrations in critically ill obese patients with ventilator-associated pneumonia: intermittent vs continuous administration. De Pascale G; Fortuna S; Tumbarello M; Cutuli SL; Vallecoccia M; Spanu T; Bello G; Montini L; Pennisi MA; Navarra P; Antonelli M Intensive Care Med; 2015 Jan; 41(1):103-10. PubMed ID: 25413377 [TBL] [Abstract][Full Text] [Related]
32. Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility. Roberts JA; Lipman J Crit Care Med; 2013 Feb; 41(2):489-95. PubMed ID: 23263583 [TBL] [Abstract][Full Text] [Related]
33. Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients. Mattioli F; Fucile C; Del Bono V; Marini V; Parisini A; Molin A; Zuccoli ML; Milano G; Danesi R; Marchese A; Polillo M; Viscoli C; Pelosi P; Martelli A; Di Paolo A Eur J Clin Pharmacol; 2016 Jul; 72(7):839-48. PubMed ID: 27048201 [TBL] [Abstract][Full Text] [Related]
34. Modified Augmented Renal Clearance score predicts rapid piperacillin and tazobactam clearance in critically ill surgery and trauma patients. Akers KS; Niece KL; Chung KK; Cannon JW; Cota JM; Murray CK J Trauma Acute Care Surg; 2014 Sep; 77(3 Suppl 2):S163-70. PubMed ID: 24770557 [TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics, toxicity and clinical efficacy of linezolid in Japanese pediatric patients. Ogami C; Tsuji Y; To H; Yamamoto Y J Infect Chemother; 2019 Dec; 25(12):979-986. PubMed ID: 31208925 [TBL] [Abstract][Full Text] [Related]
36. Suboptimal aminoglycoside dosing in critically ill patients. Rea RS; Capitano B; Bies R; Bigos KL; Smith R; Lee H Ther Drug Monit; 2008 Dec; 30(6):674-81. PubMed ID: 19057371 [TBL] [Abstract][Full Text] [Related]
37. Population Pharmacokinetics and Dosing Optimization of Linezolid in Pediatric Patients. Li SC; Ye Q; Xu H; Zhang L; Wang Y Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30642929 [TBL] [Abstract][Full Text] [Related]
38. Population pharmacokinetics and toxicodynamics of continuously infused linezolid in critically ill patients. Wicha SG; Mair A; Chiriac U; Frey OR; Fuchs T; Gaasch M; Hagel S; Richter DC; Roberts JA; Röhr AC; Weigand MA; Brinkmann A Int J Antimicrob Agents; 2022 May; 59(5):106572. PubMed ID: 35307562 [TBL] [Abstract][Full Text] [Related]
39. Population Pharmacokinetics of Colistin Methanesulfonate and Colistin in Critically Ill Patients with Acute Renal Failure Requiring Intermittent Hemodialysis. Jacobs M; Grégoire N; Mégarbane B; Gobin P; Balayn D; Marchand S; Mimoz O; Couet W Antimicrob Agents Chemother; 2016 Jan; 60(3):1788-93. PubMed ID: 26729492 [TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics and preliminary safety of high dose linezolid for the treatment of Gram-positive bacterial infections. Lopez-Garcia B; Luque S; Roberts JA; Grau S J Infect; 2015 Nov; 71(5):604-7. PubMed ID: 26099449 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]